滋肾活络方联合沙利度胺治疗多发性骨髓瘤的临床疗效研究  

Clinical study on treatment of Multiple Myeloma by homemade Zishenhuoluo formula combined with thalidomide

作　　者：史艳霞 殷晓宁[1] 李颖[2] Shi Yartxia;Ying Xiaoning;Li Ying(College of ZhangJiaKou,ZhangJiaKou 075000;Third Affiliated Hospital of Liaoning Medical University, Jinzhou 121000)

机构地区：[1]张家口学院,张家口075000 [2]辽宁医学院附属第三医院,锦州121000

出　　处：《中药药理与临床》2018年第2期122-125,共4页Pharmacology and Clinics of Chinese Materia Medica

摘　　要：目的:对自拟滋肾活络方联合沙利度胺治疗多发性骨髓瘤的临床疗效进行评价。方法:将120例多发性骨髓瘤患者分为2组进行对比治疗,其中对照组采用VAD方案,观察组在对照组的基础上使用自拟滋肾活络方联合沙利度胺治疗。结果:经过治疗后,观察组的患者总有效率达到75%,对照组的患者总有效率达到60%;M蛋白、骨髓浆细胞、破骨细胞指标与治疗前相比均下降,而观察组下降较对照组更为明显,分别为8.85±8.48,15.37±8.96,0.19±0.06;成骨细胞指标两组较治疗前上升,观察组上升较对照组更为明显为1.63±0.21。在肾功能、生活治疗和毒副作用评估上,观察组患者较对照组患者所受化疗的影响更小。结论:自拟滋肾活络方联合沙利度胺治疗多发性骨髓瘤的临床疗效更为显著,并且具有副作用较少和治疗后患者的生活质量较高的优点,具有较大的临床应用价值,值得推广。Objective： To evaluate the clinical efficacy of homemade Zishenhuoluo formula combined with thalidomide in the treatment of multiple myeloma. Methods： 120 cases of multiple myeloma patients were divided into two groups. VAD program was given to patients in the control group,homemade Zishenhuoluo formula combined with thalidomide treatment was given to them in the observation group. Results： After the treatment,the total effective rate in the observation group was 75%,and the total effective rate in the control group was 60%. There was the significant difference between two groups（ p 〈 0. 05）. M protein,bone marrow plasma cells and osteoclast markers were decreased in both groups compared with those before the treatment,while them（ 8. 85 ± 8. 48,15. 37 ± 8. 96,0. 191 ± 0. 06） in the observation group were more obvious than those in the control group（ p 〈 0. 05）. Osteoblast indexes in two groups were higher than those before the treatment,and the increase in the observation group was more significantly higher than that in the control group,the index was 1. 63 ± 0. 206（ p 〈 0. 05）.In the assessment of the renal function,life therapy and side effects in the observation group were less affected by chemotherapy than those in the control group. Conclusion： The clinical efficacy of Zishenhuoluo formula combined with thalidomide in the treatment of multiple myeloma is more significant,and it has advantages of less side effect and high quality of life of patients after the treatment,and has the great clinical application value,and worthy of promotion.

关 键 词：滋肾活络方 沙利度胺 多发性骨髓瘤 VOA方案 临床疗效 

分 类 号：R733.3[医药卫生—肿瘤]